Jianbing Wu

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

Zhenggang Ren, Jianming Xu, Yuxian Bai et al. · The Lancet Oncology · 2021 · 1K citations

Hepatology, Bevacizumab Biosimilar, Medicine +8

Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)

Hai‐Dong Zhu, Hai-Liang Li, Mingsheng Huang et al. · Signal Transduction and Targeted Therapy · 2023 · 262 citations · Full text

Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study

Qiuhe Wang, Dongdong Xia, Wei Bai et al. · Journal of Hepatology · 2019 · 252 citations

Prognostic Biomarkers, Hepatology, Medicine +8

Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study

Zhi‐Cheng Jin, Jian-Jia Chen, Xiaoli Zhu et al. · EClinicalMedicine · 2024 · 119 citations · Full text

Medicine, Immune Checkpoint Inhibitors, Immunology +9

Identification of Arp2/3 Complex Subunits as Prognostic Biomarkers for Hepatocellular Carcinoma

Shenglan Huang, Dan Li, Lingling Zhuang et al. · Frontiers in Molecular Biosciences · 2021 · 63 citations · Full text